MARKET

INMB

INMB

Inmune Bio Inc
NASDAQ
1.510
+0.090
+6.34%
After Hours: 1.480 -0.03 -1.99% 19:26 02/06 EST
OPEN
1.480
PREV CLOSE
1.420
HIGH
1.550
LOW
1.440
VOLUME
320.21K
TURNOVER
--
52 WEEK HIGH
11.64
52 WEEK LOW
1.380
MARKET CAP
40.14M
P/E (TTM)
-0.7054
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INMB last week (0126-0130)?
Weekly Report · 5d ago
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating
TipRanks · 01/28 18:15
INmune Bio outlines 2026 regulatory path in shareholder letter
TipRanks · 01/27 21:41
INmune Bio Inc. Publishes 2025 Shareholder Letter
Reuters · 01/27 21:01
INmune Bio CEO says ‘well positioned for continued execution’
TipRanks · 01/27 14:30
INMUNE BIO INC ISSUES SHAREHOLDER LETTER REVIEWING 2025 MILESTONES AND OUTLINING 2026 STRATEGIC INITIATIVES
Reuters · 01/27 14:25
Weekly Report: what happened at INMB last week (0119-0123)?
Weekly Report · 01/26 09:52
Weekly Report: what happened at INMB last week (0112-0116)?
Weekly Report · 01/19 09:57
More
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Webull offers INmune Bio Inc stock information, including NASDAQ: INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.